Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013, Article ID 510243, 10 pages
http://dx.doi.org/10.1155/2013/510243
Research Article

Marked Independent Relationship between Circulating Interleukin-6 Concentrations and Endothelial Activation in Rheumatoid Arthritis

1Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, P.O. Box 1012 Johannesburg, Melville 2109, South Africa
2Department of Rheumatology, Charlotte Maxeke Johannesburg Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, South Africa
3Milpark Hospital, Johannesburg, South Africa
4Department of Rheumatology, Hospital Universitario Marques de Valdecilla, IFIMAV, Avenida de Valdecilla s/n, 39008 Santander, Spain

Received 17 June 2013; Revised 10 November 2013; Accepted 11 November 2013

Academic Editor: Teresa Zelante

Copyright © 2013 Patrick H. Dessein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Libby, P. M. Ridker, and A. Maseri, “Inflammation and atherosclerosis,” Circulation, vol. 105, no. 9, pp. 1135–1143, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Koenig and N. Khuseyinova, “Biomarkers of atherosclerotic plaque instability and rupture,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 15–26, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Gu, Y. Okada, S. K. Clinton et al., “Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice,” Molecular Cell, vol. 2, no. 2, pp. 275–281, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. S. J. Hwang, C. M. Ballantyne, A. R. Sharrett et al., “Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk In communities (ARIC) study,” Circulation, vol. 96, no. 12, pp. 4219–4225, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Martinovic, N. Abegunewardene, M. Seul et al., “Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease,” Circulation Journal, vol. 69, no. 12, pp. 1484–1489, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. K. F. Kusano, K. Nakamura, H. Kusano et al., “Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis—assessment in chronic hemodialysis patients,” Circulation Journal, vol. 68, no. 7, pp. 671–676, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Wållberg-Jonsson, J. T. Cvetkovic, K. G. Sundqvist, A. K. Lefvert, and S. Rantapää-Dahlqvist, “Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis,” Journal of Rheumatology, vol. 29, no. 5, pp. 875–882, 2002. View at Google Scholar · View at Scopus
  9. P. H. Dessein, B. I. Joffe, and S. Singh, “Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis,” Arthritis Research & Therapy, vol. 7, no. 3, pp. 634–643, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Södergren, K. Karp, K. Boman et al., “Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness,” Arthritis Research and Therapy, vol. 12, article 158, no. 4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. H. Rho, C. P. Chung, A. Oeser et al., “Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis,” Arthritis Care and Research, vol. 61, no. 11, pp. 1580–1585, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. D. H. Solomon, N. J. Goodson, J. N. Katz et al., “Patterns of cardiovascular risk in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 65, no. 12, pp. 1608–1612, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Maradit-Kremers, C. S. Crowson, P. J. Nicola et al., “Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study,” Arthritis and Rheumatism, vol. 52, no. 2, pp. 402–411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, and J. Martin, “Rheumatoid arthritis: a disease associated with accelerated atherogenesis,” Seminars in Arthritis and Rheumatism, vol. 35, no. 1, pp. 8–17, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Gonzalez-Juanatey and M. A. Gonzalez-Gay, “Inflammation, endothelial function and atherosclerosis in rheumatoid arthritis,” Arthritis Research and Therapys, vol. 14, article 122, no. 4, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. P. H. Dessein, B. I. Joffe, M. G. Veller et al., “Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis,” Journal of Rheumatology, vol. 32, no. 3, pp. 435–442, 2005. View at Google Scholar · View at Scopus
  17. P. H. Dessein, G. R. Norton, A. J. Woodiwiss, B. I. Joffe, and F. Wolfe, “Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis,” Journal of Rheumatology, vol. 34, no. 5, pp. 943–951, 2007. View at Google Scholar · View at Scopus
  18. D. H. Solomon, J. Kremer, J. R. Curtis et al., “Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity,” Annals of the Rheumatic Diseases, vol. 69, no. 11, pp. 1920–1925, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. P. O. Bonetti, L. O. Lerman, and A. Lerman, “Endothelial dysfunction: a marker of atherosclerotic risk,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 168–175, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. P. H. Dessein and B. I. Joffe, “Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 24, no. 2, pp. 161–167, 2006. View at Google Scholar · View at Scopus
  21. M. A. Gonzales-Gay, M. T. Garcia-Unzueta, J. M. De Matias et al., “Influence of anti-TNF-alpha Infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 24, no. 4, pp. 373–379, 2006. View at Google Scholar · View at Scopus
  22. C. X. Kim, K. R. Bailey, G. G. Klee et al., “Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study,” PLoS One, vol. 5, no. 2, Article ID 9065, 2010. View at Publisher · View at Google Scholar
  23. M. Hashizume and M. Mihara, “The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis,” Arthritis, vol. 2011, Article ID 765624, 8 pages, 2011. View at Publisher · View at Google Scholar
  24. R. Woodrick and E. M. Ruderman, “Anti-interleukin-6 therapy in rheumatoid arthritis,” Bulletin of the NYU Hospital for Joint Diseases, vol. 68, no. 3, pp. 211–217, 2010. View at Google Scholar · View at Scopus
  25. M. Hashizume, H. Yoshida, N. Koike, M. Suzuki, and M. Mihara, “Overproduced interleukin-6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor,” Annals of the Rheumatic Diseases, vol. 69, no. 4, pp. 741–746, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Shimamoto, T. Ito, Y. Ozaki, H. Amuro, A. Tanaka, T. Nishizawa et al., “Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis,” The Journal of Rheumatology, vol. 40, no. 7, pp. 1074–1081, 2013. View at Publisher · View at Google Scholar
  27. A. Solomon, G. R. Norton, A. J. Woodiwiss, and P. H. Dessein, “Obesity and carotid atherosclerosis in African black and Caucasian women with established rheumatoid arthritis: a cross-sectional study,” Arthritis Research & Therapy, vol. 14, article R67, no. 2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Solomon, A. J. Woodiwiss, A. T. Abdool-Carrim, B. A. Stevens, G. R. Norton, and P. H. Dessein, “The carotid atherosclerosis burden and its relation to cardiovascular risk factors in black and white Africans with established rheumatoid arthritis: a cross-sectional study,” The Journal of Rheumatology, vol. 39, no. 9, pp. 1798–1806, 2012. View at Publisher · View at Google Scholar
  29. P. H. Dessein, G. R. Norton, B. I. Joffe, A. T. Abdool-Carrim, A. J. Woodiwiss, and A. Solomon, “Metabolic cardiovascular risk burden and atherosclerosis in African black and Caucasian women with rheumatoid arthritis: a cross-sectional study,” Clinical and Experimental Rheumatology, vol. 31, no. 1, pp. 53–61, 2013. View at Google Scholar
  30. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Solomon, B. F. Christian, G. R. Norton, A. J. Woodiwiss, and P. H. Dessein, “Risk factor profiles for atherosclerotic cardiovascular disease in black and other africans with established rheumatoid arthritis,” Journal of Rheumatology, vol. 37, no. 5, pp. 953–960, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. P. H. Dessein, B. F. Christian, and A. Solomon, “Which are the determinants of dyslipidemia in rheumatoid arthritis and does socioeconomic status matter in this context?” The Journal of Rheumatology, vol. 36, no. 7, pp. 1357–1361, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation,” Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. T. T. Heiberg, T. K. Kvien, P. Mowinckel, D. Aletaha, J. S. Smolen, and K. B. Hagen, “Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 67, no. 7, pp. 967–971, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. T. A. Pearson, G. A. Mensah, R. W. Alexander et al., “Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the american heart association,” Circulation, vol. 107, no. 3, pp. 499–511, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. P. M. Ridker, “C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus,” Journal of the American College of Cardiology, vol. 49, no. 21, pp. 2129–2138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. P. H. Dessein, G. R. Norton, A. J. Woodiwiss, and A. Solomon, “Independent relationship between circulating resistin concentrations and endothelial activation in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 72, no. 9, pp. 1586–1588, 2013. View at Publisher · View at Google Scholar
  38. B. Heinhuis, C. Popa, B. L. van Tits et al., “Towards a role of interleukin 32 in atherosclerosis,” Cytokine, vol. 64, no. 1, pp. 433–440, 2013. View at Publisher · View at Google Scholar
  39. A. Vaglio, M. G. Cantanaso, L. Magnani, N. Pipitone, P. Macchioni, L. Spaggiari et al., “Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis,” Arthritis and Rheumatism, vol. 65, no. 9, pp. 2459–2475, 2013. View at Publisher · View at Google Scholar
  40. M. Fabris, L. Quartuccio, S. Lombardi et al., “Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximabin rheumatoid arthritis,” Reumatismo, vol. 62, no. 4, pp. 253–258, 2010. View at Google Scholar · View at Scopus
  41. J. S. Smolen, M. M. Schoels, N. Nishimoto et al., “Consensus statement on blocking the effects of interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions,” Annals of the Rheumatic Diseases, vol. 72, no. 4, pp. 482–492, 2013. View at Publisher · View at Google Scholar
  42. Z. Lu, Y. Li, J. Jin, X. Zhang, M. F. Lopes-Virella, and Y. Huang, “Toll-like receptor 4 activation in microvascular endothelial cells triggers a robust inflammatory response and cross talk with mononuclear cells via interleukin-6,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 7, pp. 1696–1706, 2012. View at Publisher · View at Google Scholar
  43. A. Mantovani, F. Bussolino, and E. Dejana, “Cytokine regulation of endothelial cell function,” The Journal of the Federation of American Societies for Experimental Biology, vol. 6, no. 8, pp. 2591–2599, 1992. View at Google Scholar · View at Scopus
  44. V. Marin, F. A. Montero-Julian, S. Grès et al., “The IL-6-soluble IL-6Rα autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin,” The Journal of Immunology, vol. 167, no. 6, pp. 3435–3442, 2001. View at Google Scholar · View at Scopus
  45. C. Viedt, J. Vogel, T. Athanasiou et al., “Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-κB and activator protein-1,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 6, pp. 914–920, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. M. C. Genovese, J. D. McKay, E. L. Nasonov et al., “Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study,” Arthritis and Rheumatism, vol. 58, no. 10, pp. 2968–2980, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Luc, J. M. Bard, I. Juhan-Vague et al., “C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 7, pp. 1255–1261, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. M. J. L. Peters, D. P. M. Symmons, D. McCarey et al., “EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis,” Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 325–331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. K. P. Liao and D. H. Solomon, “Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.,” Rheumatology, vol. 52, no. 1, pp. 45–52, 2013. View at Publisher · View at Google Scholar
  50. P. H. Dessein and A. G. Semb, “Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced?” Annals of the Rheumatic Diseases, vol. 72, no. 11, pp. 1743–1746, 2013. View at Publisher · View at Google Scholar
  51. A. Corrales, C. Gonzalez-Juanatey, M. E. Peiro et al., “Carotid ultrasound is useful for cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study,” Annals of the Rheumatic Diseases, 2013. View at Publisher · View at Google Scholar
  52. B. Zethelius, L. Berglund, J. Sundström et al., “Use of multiple biomarkers to improve the prediction of death from cardiovascular causes,” The New England Journal of Medicine, vol. 358, no. 20, pp. 2107–2116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Prugger, G. Luc, B. Haas, P. E. Morange, J. Ferrieres, P. Amouyel et al., “Multiple biomarkers for the prediction of ischemic stroke: the PRIME study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 3, pp. 659–666, 2013. View at Publisher · View at Google Scholar
  54. P. H. Dessein and B. I. Joffe, “Insulin resistance and impaired beta cell function in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 9, pp. 2765–2775, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Stavropoulos-Kalinoglou, G. S. Metsios, V. F. Panoulas et al., “Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 2, pp. 242–245, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Myasoedova, C. S. Crowson, H. M. Kremers et al., “Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease,” Annals of the Rheumatic Diseases, vol. 70, no. 3, pp. 482–487, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. H. M. Kremers, P. J. Nicola, C. S. Crowson, K. V. Ballman, and S. E. Gabriel, “Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 50, no. 11, pp. 3450–3457, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Escalante, R. W. Haas, and I. Del Rincón, “Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation,” Archives of Internal Medicine, vol. 165, no. 14, pp. 1624–1629, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Ross, M. Eren, S. Murphy, H. Zhang, C. S. Thaxton, J. Chowaniec J et al., “A novel mouse model that develops spontaneous arthritis and is predisposed towards atherosclerosis,” Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 89–95, 2013. View at Publisher · View at Google Scholar
  60. E. Choy and N. Sattar, “Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions,” Annals of the Rheumatic Diseases, vol. 68, no. 4, pp. 460–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. M. McMahon, J. Grossman, J. FitzGerald et al., “Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 8, pp. 2541–2549, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. B. H. Hahn, J. Grossman, A. J. Ansell, B. J. Skaggs, and M. McMahon, “Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis,” Arthritis Research and Therapy, vol. 10, article 213, no. 4, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. I. Del Rincón, D. H. O'Leary, R. W. Haas, and A. Escalante, “Effect of glucocorticoids on the arteries in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 50, no. 12, pp. 3813–3822, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. J. M. Davis III, H. M. Kremers, C. S. Crowson et al., “Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study,” Arthritis and Rheumatism, vol. 56, no. 3, pp. 820–830, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. D. J. Brotman, J. P. Girod, M. J. Garcia et al., “Effects of short-term glucocorticoids on cardiovascular biomarkers,” The Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 6, pp. 3202–3208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. M. A. Gonzalez-Gay, “Glucocorticoid-related cardiovascular and cerebrovascular events in rheumatic diseases: myth or reality?” Arthritis and Rheumatism, vol. 57, no. 2, pp. 191–192, 2007. View at Publisher · View at Google Scholar · View at Scopus